Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alitretinoin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Alitretinoin | DRUG | - |
Inclusion Criteria Patients must have: * HIV positive status and histologic confirmation of KS. * CD4 count \> 200 mm3 (required of one-half of patients). * Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting criteria for "indicator" lesions. * Acceptable organ syste...
Alitretinoin is an investigational small molecule being studied for AIDS-related Kaposi sarcoma, a cancer that occurs in people with HIV infection. Ligand Pharmaceuticals Incorporated is developing it in this oncology indication. It has been evaluated in a Phase 2 trial in patients with AIDS-related Kaposi sarcoma and HIV infection.
Alitretinoin targets the retinoid X receptors RXRA, RXRB, and RXRG and the retinoic acid receptors RARA, RARB, and RARG. It acts as an agonist at these receptors, meaning it activates them. This receptor activity is the basis for its investigation in Kaposi sarcoma.
Ligand Pharmaceuticals Incorporated, which trades under the ticker LGND, is the developer of alitretinoin. The company is studying the small molecule in oncology, specifically for AIDS-related Kaposi sarcoma.
Alitretinoin is in Phase 2 development for AIDS-related Kaposi sarcoma. It is investigational and has not been approved for this indication. The Phase 2 study has been completed, and no trials of alitretinoin are currently active.
Alitretinoin has been studied in one completed Phase 2 trial, NCT00002188, titled A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma. The trial enrolled 27 patients aged 18 years and older with Kaposi sarcoma and HIV infection. It was an uncontrolled, open-label study.